# Starling Oncology, Inc.: financial statements, quarterly

STLN · Nasdaq · CIK 1799191 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/stln.md) · [Financials](/companies/stln/financials.md) · [Filings](/companies/stln/filings.md) · [Insiders](/companies/stln/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/stln/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [82.0](/filings/0001799191-24-000030.md) | [85.8 d](/filings/0001799191-25-000014.md) | [94.7](/filings/0001628280-25-025507.md) | [98.6](/filings/0001628280-25-040225.md) | [99.9](/filings/0001799191-25-000036.md) | [100 d](/filings/0001799191-26-000007.md) | [104](/filings/0001799191-26-000010.md) | [120](/filings/0001799191-26-000017.md) | [137](/filings/0001799191-25-000036.md) | [142 d](/filings/0001799191-26-000007.md) | [147](/filings/0001799191-26-000010.md) | [161](/filings/0001799191-26-000017.md) |
| Selling, general and administrative | $m | [28.2](/filings/0001799191-24-000030.md) | [28.1 d](/filings/0001799191-25-000014.md) | [28.5](/filings/0001628280-25-025507.md) | [27.9](/filings/0001628280-25-040225.md) | [26.6](/filings/0001799191-25-000036.md) | [24.9 d](/filings/0001799191-26-000007.md) | [25.4](/filings/0001799191-26-000010.md) | [26.9](/filings/0001799191-26-000017.md) | [25.3](/filings/0001799191-25-000036.md) | [28.0 d](/filings/0001799191-26-000007.md) | [28.2](/filings/0001799191-26-000010.md) | [29.9](/filings/0001799191-26-000017.md) |
| Operating income | $m | [(13.9)](/filings/0001799191-24-000030.md) | [(15.3) d](/filings/0001799191-25-000014.md) | [(18.0)](/filings/0001628280-25-025507.md) | [(16.4)](/filings/0001628280-25-040225.md) | [(13.9)](/filings/0001799191-25-000036.md) | [(11.9) d](/filings/0001799191-26-000007.md) | [(9.9)](/filings/0001799191-26-000010.md) | [(11.2)](/filings/0001799191-26-000017.md) | [(8.1)](/filings/0001799191-25-000036.md) | [(6.9) d](/filings/0001799191-26-000007.md) | [(6.5)](/filings/0001799191-26-000010.md) | [(4.6)](/filings/0001799191-26-000017.md) |
| Interest expense | $m | [1.8](/filings/0001799191-24-000030.md) | [1.9 d](/filings/0001799191-25-000014.md) | [2.0](/filings/0001628280-25-025507.md) | [2.1](/filings/0001628280-25-040225.md) | [2.2](/filings/0001799191-25-000036.md) | [1.2 d](/filings/0001799191-26-000007.md) | [5.6](/filings/0001799191-26-000010.md) | [1.9](/filings/0001799191-26-000017.md) | [1.9](/filings/0001799191-25-000036.md) | [1.9 d](/filings/0001799191-26-000007.md) | [1.9](/filings/0001799191-26-000010.md) | [1.9](/filings/0001799191-26-000017.md) |
| Income tax | $m | [0.1](/filings/0001799191-24-000030.md) | [(0.3) d](/filings/0001799191-25-000014.md) | [0.0](/filings/0001628280-25-025507.md) | [0.0](/filings/0001628280-25-040225.md) | [0.0](/filings/0001799191-25-000036.md) | [0.0 d](/filings/0001799191-26-000007.md) | [0.0](/filings/0001799191-26-000010.md) | [(0.1)](/filings/0001799191-26-000017.md) | [0.0](/filings/0001799191-25-000036.md) | [0.0 d](/filings/0001799191-26-000007.md) | [0.0](/filings/0001799191-26-000010.md) | [0.0](/filings/0001799191-26-000017.md) |
| Net income | $m | [(17.4)](/filings/0001799191-24-000030.md) | [(18.8) d](/filings/0001799191-25-000014.md) | [(19.9)](/filings/0001799191-25-000036.md) | [(15.5)](/filings/0001799191-25-000036.md) | [(16.1)](/filings/0001799191-25-000036.md) | [(13.2) d](/filings/0001799191-26-000007.md) | [(19.6)](/filings/0001799191-26-000017.md) | [(17.0)](/filings/0001799191-26-000017.md) | [(16.5)](/filings/0001799191-25-000036.md) | [(7.5) d](/filings/0001799191-26-000007.md) | [(2.5)](/filings/0001799191-26-000017.md) | [(9.8)](/filings/0001799191-26-000017.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0001799191-24-000030.md) | not reported | [(0.22)](/filings/0001628280-25-025507.md) | [(0.17)](/filings/0001628280-25-040225.md) | [(0.18)](/filings/0001799191-25-000036.md) | not reported | [(0.21)](/filings/0001799191-26-000010.md) | [(0.15)](/filings/0001799191-26-000017.md) | [(0.14)](/filings/0001799191-25-000036.md) | not reported | [(0.02)](/filings/0001799191-26-000010.md) | [(0.08)](/filings/0001799191-26-000017.md) |
| Basic EPS | $ per share | [(0.19)](/filings/0001799191-24-000030.md) | not reported | [(0.22)](/filings/0001628280-25-025507.md) | [(0.17)](/filings/0001628280-25-040225.md) | [(0.18)](/filings/0001799191-25-000036.md) | not reported | [(0.21)](/filings/0001799191-26-000010.md) | [(0.15)](/filings/0001799191-26-000017.md) | [(0.14)](/filings/0001799191-25-000036.md) | not reported | [(0.02)](/filings/0001799191-26-000010.md) | [(0.08)](/filings/0001799191-26-000017.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [153](/filings/0001628280-23-037896.md) | [143](/filings/0001799191-25-000014.md) | [141](/filings/0001628280-24-023223.md) | [116](/filings/0001799191-24-000022.md) | [116](/filings/0001799191-24-000030.md) | [112](/filings/0001799191-26-000007.md) | [107](/filings/0001628280-25-025507.md) | [105](/filings/0001628280-25-040225.md) | [110](/filings/0001799191-25-000036.md) | [113](/filings/0001799191-26-000017.md) | [117](/filings/0001799191-26-000010.md) | [129](/filings/0001799191-26-000017.md) |
| Total assets | $m | [218](/filings/0001628280-23-037896.md) | [209](/filings/0001799191-25-000014.md) | [205](/filings/0001628280-24-023223.md) | [180](/filings/0001799191-24-000022.md) | [179](/filings/0001799191-24-000030.md) | [173](/filings/0001799191-26-000007.md) | [164](/filings/0001628280-25-025507.md) | [160](/filings/0001628280-25-040225.md) | [164](/filings/0001799191-25-000036.md) | [165](/filings/0001799191-26-000017.md) | [168](/filings/0001799191-26-000010.md) | [178](/filings/0001799191-26-000017.md) |
| Current liabilities | $m | [32.4](/filings/0001628280-23-037896.md) | [34.8](/filings/0001799191-25-000014.md) | [45.8](/filings/0001628280-24-023223.md) | [35.1](/filings/0001799191-24-000022.md) | [46.8](/filings/0001799191-24-000030.md) | [52.2](/filings/0001799191-26-000007.md) | [59.5](/filings/0001628280-25-025507.md) | [64.8](/filings/0001628280-25-040225.md) | [65.6](/filings/0001799191-25-000036.md) | [71.0](/filings/0001799191-26-000017.md) | [79.4](/filings/0001799191-26-000010.md) | [94.9](/filings/0001799191-26-000017.md) |
| Total liabilities | $m | [147](/filings/0001628280-23-037896.md) | [152](/filings/0001799191-25-000014.md) | [163](/filings/0001628280-24-023223.md) | [150](/filings/0001799191-24-000022.md) | [164](/filings/0001799191-24-000030.md) | [169](/filings/0001799191-26-000007.md) | [159](/filings/0001628280-25-025507.md) | [169](/filings/0001628280-25-040225.md) | [176](/filings/0001799191-25-000036.md) | [180](/filings/0001799191-26-000017.md) | [185](/filings/0001799191-26-000010.md) | [203](/filings/0001799191-26-000017.md) |
| Long-term debt | $m | [85.3](/filings/0001628280-23-037896.md) | [86.8](/filings/0001799191-25-000014.md) | [88.4](/filings/0001628280-24-023223.md) | [90.0](/filings/0001799191-24-000022.md) | [91.5](/filings/0001799191-24-000030.md) | [93.1](/filings/0001799191-26-000007.md) | [73.9](/filings/0001628280-25-025507.md) | [75.0](/filings/0001628280-25-040225.md) | [76.2](/filings/0001799191-25-000036.md) | [77.4](/filings/0001799191-26-000017.md) | [78.6](/filings/0001799191-26-000010.md) | [79.9](/filings/0001799191-26-000017.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [71.8](/filings/0001799191-24-000030.md) | [57.0](/filings/0001799191-26-000007.md) | [41.3](/filings/0001799191-25-000036.md) | [29.2](/filings/0001799191-25-000036.md) | [15.5](/filings/0001799191-25-000036.md) | [3.6](/filings/0001799191-26-000017.md) | [5.1](/filings/0001799191-26-000017.md) | [(9.0)](/filings/0001799191-26-000017.md) | [(12.3)](/filings/0001799191-25-000036.md) | [(15.7)](/filings/0001799191-26-000017.md) | [(16.3)](/filings/0001799191-26-000017.md) | [(24.9)](/filings/0001799191-26-000017.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.3) d](/filings/0001799191-24-000030.md) | [(3.9) d](/filings/0001799191-25-000014.md) | [(15.9)](/filings/0001628280-25-025507.md) | [(15.7) d](/filings/0001628280-25-040225.md) | [0.8 d](/filings/0001799191-25-000036.md) | [4.0](/filings/0001799191-25-000014.md) | [(5.0)](/filings/0001799191-26-000010.md) | [(10.2) d](/filings/0001799191-26-000017.md) | [(12.6) d](/filings/0001799191-25-000036.md) | [3.2 d](/filings/0001799191-26-000007.md) | [(2.2)](/filings/0001799191-26-000010.md) | [11.9 d](/filings/0001799191-26-000017.md) |
| Capital expenditure | $m | [0.9 d](/filings/0001799191-24-000030.md) | [0.9 d](/filings/0001799191-25-000014.md) | [0.6](/filings/0001628280-25-025507.md) | [1.8 d](/filings/0001628280-25-040225.md) | [(0.4) d](/filings/0001799191-25-000036.md) | [1.8 d](/filings/0001799191-26-000007.md) | [0.3](/filings/0001799191-26-000010.md) | [1.2 d](/filings/0001799191-26-000017.md) | [0.6 d](/filings/0001799191-25-000036.md) | [1.1 d](/filings/0001799191-26-000007.md) | [1.0](/filings/0001799191-26-000010.md) | [0.9 d](/filings/0001799191-26-000017.md) |
| Share repurchases | $m | [0.1 d](/filings/0001799191-24-000030.md) | [0.0 d](/filings/0001799191-25-000014.md) | not reported | not reported | [0.0 d](/filings/0001799191-24-000030.md) | [0.0 d](/filings/0001799191-25-000014.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [79.6](/filings/0001628280-23-037896.md) | [73.4](/filings/0001628280-24-023223.md) | [74.1](/filings/0001799191-24-000022.md) | [73.5](/filings/0001799191-24-000030.md) | [74.2](/filings/0001628280-25-025507.md) | [74.7](/filings/0001628280-25-040225.md) | [75.5](/filings/0001799191-25-000036.md) | [77.1](/filings/0001799191-26-000010.md) | [93.2](/filings/0001799191-26-000017.md) | [97.5](/filings/0001799191-25-000036.md) | [102](/filings/0001799191-26-000010.md) | [103](/filings/0001799191-26-000017.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 101,916,115 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001799191-26-000017.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.